Introduction: The recommendations of the current guidelines are based on low quality evidence. Periodic updating is required, taking recent evidence into consideration.
Objective: To synthesise the best available clinical evidence on the efficacy and safety of second-generation antidepressants and antipsychotics in patients with anorexia nervosa.
Methods: Systematic review (CRD42020150577). We searched PubMed, SCOPUS, Ovid(Cochrane), EMBASE and LILACS for randomised clinical trials performed in patients with anorexia nervosa that evaluated the use of second-generation antipsychotics or oral antidepressants, at any dose and for any length of time, in outpatient and/or hospital treatment, taking weight (body mass index), psychopathological entities and safety as results.
Results: Five studies were included, with four assessed as having a high risk of bias. The evidence indicates that patients receiving treatment with olanzapine or fluoxetine tend to stay in treatment programmes for longer. Olanzapine showed favourable results (one study) in terms of weight gain, but did not show the same results in psychopathology, where the evidence is contradictory.
Conclusions: In accordance with previous reviews, our work allows us to conclude that there is contradictory information on the efficacy of psychotropic drugs in the treatment of anorexia nervosa. Future work should focus on developing clinical trials of high methodological quality.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.rcp.2020.11.009 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Demographics, psychiatric comorbidities, and hospital outcomes across eating disorder types in adolescents and youth: insights from US hospitals data.
Front Child Adolesc Psychiatry
May 2024
Department of Psychiatry & Behavioral Sciences, School of Medicine, Duke University, Durham, NC, United States.
Objective: The aim of our study was to delineate the differences in demographics, comorbidities, and hospital outcomes by eating disorder types in adolescents and transitional-age youth (15-26 years), and measure the association with psychiatric comorbidities.
Methods: We conducted a cross-sectional study using the nationwide inpatient sample (2018-2019) and included 7,435 inpatients (age 12-24 years) with a primary diagnosis of eating disorders: anorexia nervosa (AN, 71.7%), bulimia nervosa (BN, 4.
Efficacy of transcranial magnetic stimulation in anorexia nervosa: a systematic review and meta-analysis.
Eat Weight Disord
January 2025
Iranian Center of Neurological Research, Neuroscience Institute, Tehran University of Medical Sciences, Tehran, Iran.
Purpose: Transcranial magnetic stimulation (TMS) has emerged as a promising treatment for various neuropsychiatric conditions, including depression, obsessive-compulsive disorder, and Parkinson's disease. Recent research has focused on evaluating its effectiveness in treating patients with anorexia nervosa (AN). This systematic review and meta-analysis examined the impact of TMS on patients with AN and evaluated any potential adverse effects.
View Article and Find Full Text PDFThe current clinical approach to feeding and eating disorders aimed to increase personalization of management.
World Psychiatry
February 2025
School of Health in Social Science, University of Edinburgh, Edinburgh, UK.
Feeding and eating disorders (FEDs) are a heterogeneous grouping of disorders at the mind-body interface, with typical onset from childhood into emerging adulthood. They occur along a spectrum of disordered eating and compensatory weight management behaviors, and from low to high body weight. Psychiatric comorbidities are the norm.
View Article and Find Full Text PDFTargeting the gut microbiota-inflammation-brain axis as a potential therapeutic strategy for psychiatric disorders: A Mendelian randomization analysis.
J Affect Disord
January 2025
School of Nursing, Guangzhou Medical University, Guangzhou, Guangdong Province, China. Electronic address:
Background: Extensive research indicates a link between gut microbiota dysbiosis and psychiatric disorders. However, the causal relationships between gut microbiota and different types of psychiatric disorders, as well as whether inflammatory factors mediate these relationships, remain unclear.
Methods: We utilized summary statistics from the largest genome-wide association studies to date for gut microbiota (n = 18,340 in MiBioGen consortium), circulating inflammatory factors (n = 8293 for 41 factors and n = 14,824 for 91 factors in GWAS catalog), and six major psychiatric disorders from the Psychiatric Genomics Consortium (PGC): attention deficit hyperactivity disorder (ADHD, n = 38,691), anxiety disorder (ANX, n = 2248), bipolar disorder (BIP, n = 41,917), anorexia nervosa (AN, n = 16,992), schizophrenia (SCZ, n = 36,989), and autism spectrum disorder (ASD, n = 18,381).
Examining the associations between laxative use, substance use, depressive symptoms, and obsessions and compulsions in adults with an eating disorder.
J Psychiatr Res
December 2024
Department of Behavioral Sciences, College of Health Sciences, Clinical Psychology Program, Midwestern University, 19555 N 59th Ave, Glendale, AZ, 85308, USA.
This study examined laxative and substance use in adults with an eating disorder, and the association with depression, compulsions, and obsessions. A retrospective chart review of 182 women who had a formal diagnosis of an eating disorder and were receiving specialized outpatient treatment was conducted. The chart review included questionnaires completed at intake assessment, including a demographic survey with questions asking about laxative use, substance use, and the types of substances used.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!